Changes in serotype distribution may hamper efficacy of pneumococcal conjugate vaccines in children.
During the last 10 y we have observed an increased incidence of pneumococcal bacteremia in Sweden. In order to study the serotype distribution over time we collected 1136 invasive pneumococcal isolates from 1987, 1992 and 1997 from Swedish microbiological laboratories. Currently, new pneumococcal conjugate vaccines are being considered for introduction in the general childhood vaccination program in several countries, including Sweden. We studied the potential vaccine coverage rate for the new conjugate vaccines among our Swedish invasive isolates. We found that the serotype distribution fluctuated with time and observed a surprisingly low potential coverage rate for the 7-valent vaccine in Sweden, in contrast to other countries. Therefore we argue that pneumococcal conjugate vaccines have to be tailored to suit current, local serotype patterns and most likely will need to be changed over time.
Normark
B H
BH
Department of Bacteriology, Swedish Institute for Infectious Disease Control, Solna. Birgitta.Henriques@smi.ki.se
Ortqvist
A
A
Kalin
M
M
Olsson-Liljequist
B
B
Hedlund
J
J
Svenson
S B
SB
Källenius
G
G
D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D022242:Pneumococcal Vaccines / Q000627:therapeutic use*; D011018:Pneumonia, Pneumococcal / Q000517:prevention & control*; D012307:Risk Factors; D012703:Serotyping; D013548:Sweden; D013997:Time Factors; D016896:Treatment Outcome; D018074:Vaccines, Conjugate / Q000627:therapeutic use
D022242:Pneumococcal Vaccines; D018074:Vaccines, Conjugate